Ambrx & Merck Serono deal for MS drug candidate
Submitted by art on Fri, 2009-04-03 07:32.
Ambrx Inc and Merck Serono announced a global strategic collaboration to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by Ambrx through the application of its proprietary protein optimization technology, ReCODE(TM).
Not much detail in the article, but another one to be watching.